Detalhe da pesquisa
1.
Molecular and clinical presentation of UBA1-mutated myelodysplastic syndromes.
Blood
; 2024 04 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-38687605
2.
SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS.
Blood
; 136(2): 157-170, 2020 07 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32347921
3.
Identification of a BRCA1-mRNA splicing complex required for efficient DNA repair and maintenance of genomic stability.
Mol Cell
; 54(3): 445-59, 2014 May 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-24746700
4.
Phospholipase C beta1 (PI-PLCbeta1)/Cyclin D3/protein kinase C (PKC) alpha signaling modulation during iron-induced oxidative stress in myelodysplastic syndromes (MDS).
FASEB J
; 34(11): 15400-15416, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32959428
5.
BCL-2 Inhibitor ABT-737 Effectively Targets Leukemia-Initiating Cells with Differential Regulation of Relevant Genes Leading to Extended Survival in a NRAS/BCL-2 Mouse Model of High Risk-Myelodysplastic Syndrome.
Int J Mol Sci
; 22(19)2021 Sep 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-34638998
6.
Impact of spliceosome mutations on RNA splicing in myelodysplasia: dysregulated genes/pathways and clinical associations.
Blood
; 132(12): 1225-1240, 2018 09 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-29930011
7.
Gene expression and risk of leukemic transformation in myelodysplasia.
Blood
; 130(24): 2642-2653, 2017 12 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-29097382
8.
Reduced DOCK4 expression leads to erythroid dysplasia in myelodysplastic syndromes.
Proc Natl Acad Sci U S A
; 112(46): E6359-68, 2015 Nov 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-26578796
9.
Spliceosome mutations: 1 plus 1 does not always equal 2.
Blood
; 136(13): 1471-1472, 2020 09 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-32970807
10.
IL8-CXCR2 pathway inhibition as a therapeutic strategy against MDS and AML stem cells.
Blood
; 125(20): 3144-52, 2015 May 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-25810490
11.
Progression in patients with low- and intermediate-1-risk del(5q) myelodysplastic syndromes is predicted by a limited subset of mutations.
Haematologica
; 102(3): 498-508, 2017 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-27884971
12.
The Effects of Severe Hypoxia on Glycolytic Flux and Enzyme Activity in a Model of Solid Tumors.
J Cell Biochem
; 117(8): 1890-901, 2016 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-26755257
13.
Expression of CDKN1C in the bone marrow of patients with myelodysplastic syndrome and secondary acute myeloid leukemia is associated with poor survival after conventional chemotherapy.
Int J Cancer
; 139(6): 1402-13, 2016 09 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-27170453
14.
Aberrant overexpression of CD14 on granulocytes sensitizes the innate immune response in mDia1 heterozygous del(5q) MDS.
Blood
; 124(5): 780-90, 2014 Jul 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-24891322
15.
TP53 suppression promotes erythropoiesis in del(5q) MDS, suggesting a targeted therapeutic strategy in lenalidomide-resistant patients.
Proc Natl Acad Sci U S A
; 110(40): 16127-32, 2013 Oct 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-24043769
16.
CSNK1A1 mutations and gene expression analysis in myelodysplastic syndromes with del(5q).
Br J Haematol
; 171(2): 210-214, 2015 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-26085061
17.
miR-21 mediates hematopoietic suppression in MDS by activating TGF-ß signaling.
Blood
; 121(15): 2875-81, 2013 Apr 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-23390194
18.
Clinical and biological implications of driver mutations in myelodysplastic syndromes.
Blood
; 122(22): 3616-27; quiz 3699, 2013 Nov 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-24030381
19.
The molecular pathogenesis of the myelodysplastic syndromes.
Eur J Haematol
; 95(1): 3-15, 2015 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-25645650
20.
Application of CRISPR/Cas9 genome editing to the study and treatment of disease.
Arch Toxicol
; 89(7): 1023-34, 2015 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-25827103